Results of the Extraordinary General Meeting on February 27, 2026
On February 27, 2026, the VERAXA shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company. Both resolutions are prerequisites for the closing of the proposed business combination among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ: VACH). The agenda item was approved by a majority of 12,680,593 votes, representing 99.57% of the share capital present.
The merger will be carried out by means of an absorption merger. Veraxa Biotech Holding AG, as the acquiring company, will take over VERAXA as the transferring company and simultaneously change its name to Veraxa Biotech AG. VERAXA will continue to operate under its existing management team led by Chief Executive Officer, Christoph Antz. Additionally, the EGM approved an ordinary capital increase of a maximum of CHF 223,400.00 and offering the corresponding number of shares to the shareholders of Voyager in connection with the business combination.
Subject to the approval of Voyager’s shareholders, VERAXA and Voyager will commence final procedures towards closing the Business Combination and the expected trading of shares of the combined company on NASDAQ under the symbol “VRXA”. The resolutions of the EGM are subject to the condition of the approval of the Business Combination by Voyager’s shareholders.
We appreciate our shareholders’ support and their approval to take the next steps in our business combination process with Voyager.
Kind regards,
Oliver R. Baumann, President of the Board of Directors
David L. Deck, Member of the Board of Directors